A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC
| Condition | Non-Small Cell Lung Cancer |
|---|---|
| Phase | Phase 2 |
| Sponsor | AstraZeneca |
| Status | Active, not recruiting |
| Enrollment | 30 participants |
| Interventions | Osimertinib + Savolitinib, Savolitinib + Placebo |
| Start date | Sep 28, 2020 |
| Completion date | Dec 21, 2022 |
| Results posted | Sep 24, 2024 |
Summary
This study will compare the activity of the combination of savolitinib and osimertinib against the combination of savolitinib with placebo to osimertinib in patients with Epidermal Growth Factor Receptor Mutation Positive and MET amplified, locally advanced or metastatic non-small cell lung cancer who have progressed following treatment with osimertinib.
Objective Response Rate (ORR)
| Savolitinib Plus Osimertinib | 57.1 Percentage of participants |
|---|---|
| Savolitinib Plus Placebo | 12.5 Percentage of participants |
Open in BENITIONS View on ClinicalTrials.gov
Other trials for this condition
- A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients W — AstraZeneca
- Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With — National Cancer Institute (NCI)
- Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Pos — National Cancer Institute (NCI)
- Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage I — National Cancer Institute (NCI)
- Premedication to Reduce Amivantamab Associated Infusion Related Reactions — Janssen Research & Development, LLC
- A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab — Janssen Research & Development, LLC